Gilead Sciences (GILD) and Johnson & Johnson (JNJ) win FDA approval of a once-daily HIV...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD) and Johnson & Johnson (JNJ) win FDA approval of a once-daily HIV treatment that combines multiple medicines into one tablet. The combination product, called Complera, is expected to generate $567M in revenue in 2013, a Lazard analyst says. GILD +2.5%, JNJ +0.9% AH.